ProQR Therapeutics (PRQR) Projected to Post Quarterly Earnings on Thursday

ProQR Therapeutics (NASDAQ:PRQR) is expected to be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $7.0520 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Friday, November 14, 2025 at 9:30 AM ET.

ProQR Therapeutics (NASDAQ:PRQR) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). The business had revenue of $4.33 million during the quarter, compared to analysts’ expectations of $5.01 million. ProQR Therapeutics had a negative return on equity of 61.25% and a negative net margin of 238.52%. On average, analysts expect ProQR Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ProQR Therapeutics Trading Down 8.1%

Shares of PRQR opened at $2.38 on Wednesday. The firm has a fifty day moving average price of $2.40 and a 200-day moving average price of $2.10. The firm has a market capitalization of $250.40 million, a P/E ratio of -5.17 and a beta of 0.16. ProQR Therapeutics has a 12-month low of $1.07 and a 12-month high of $4.21.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Chardan Capital restated a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Tuesday. Zacks Research cut ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Wednesday, October 8th. Finally, Evercore ISI reiterated an “outperform” rating on shares of ProQR Therapeutics in a report on Friday, July 11th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.14.

Institutional Trading of ProQR Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of PRQR. Osaic Holdings Inc. increased its holdings in shares of ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 4,500 shares during the period. Jane Street Group LLC boosted its position in ProQR Therapeutics by 699.3% during the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 79,720 shares in the last quarter. Bank of America Corp DE grew its stake in ProQR Therapeutics by 25.7% in the second quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 24,347 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in ProQR Therapeutics by 28.4% in the second quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 26,893 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).